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AbsTrACT
background/aims Assess whether a new clinical 
pathway for glaucoma was acceptable to patients 
and healthcare professionals and whether it provided 
useful clinical information on non- responsiveness and 
non- adherence to the treatment of elevated intraocular 
pressure with latanoprost eye drops.
Methods A single arm non- randomised prospective 
observational study incorporating new glaucoma/ocular 
hypertension patients. To assess issues of acceptability, 
qualitative observation and interviews were conducted 
with patients and healthcare professionals. To determine 
clinical responsiveness, intraocular pressures were 
measured before and 4 hours after a clinician- instilled 
eye drop over two distinct appointments. Adherence 
data were collected using a Medicine Event Monitoring 
System. Economic analyses compared the costs between 
novel and standard care pathways.
results Of 72 patients approached, 53 entered 
the study (74.3%) and 50 completed all procedures 
(94.3%). Intraocular pressure was reduced more than 
15% in 83 out of 92 study eyes by final visit (90.2%). 
The non- response rate was 5.1% once the effect of low 
adherence was minimised. For the 1376 drop instillation 
days under observation, eye drops were instilled as 
prescribed on 1004 days (73.0%), over- instilled on 137 
days (9.9%) and not instilled on 235 days (17.1%). The 
Cardiff Model of Glaucoma Care involved negligible 
cost, although acceptance for healthcare professionals 
showed variation.
Conclusions The Cardiff Model of Glaucoma 
Care offers novel clinical and adherence insights at 
marginal costs while acceptable to patients. Healthcare 
professionals felt that 4 hour and 4 week follow- up 
appointments could cause administrative problems. A 
streamlined version of the pathway has therefore been 




Xalatan (latanoprost) is commonly used as the first- 
line eye drop medication for treatment of glaucoma, 
the leading cause of permanent blindness world-
wide.1 Prostaglandins lower intraocular pressure 
(IOP) by increasing uveoscleral outflow and have 
been shown to be safe and efficacious since their 
introduction in 1996.2 However, some patients do 
not respond to treatment with an ongoing debate 
regarding actual non- response rates (online supple-
mentary table 1). When patients present in outpa-
tient clinics with higher- than- expected IOP despite 
being prescribed ocular hypotensive eye drops, the 
physician is faced with a dilemma since IOP reflects 
(i) the patient’s physiological response to the eye 
drops (pharmacogenetics) and (ii) a patient’s level 
of adherence to eye drops (behaviour).3 4 Current 
clinical pathways do not usually distinguish between 
these pharmacogenetic and behavioural elements of 
IOP. Physicians commonly assume a poor response 
rather than poor adherence, adding alternate or 
additional medications to obtain the desired reduc-
tion in IOP. This approach is illogical in absence 
of information regarding the patients’ response to 
medication or their adherence level. Furthermore, 
this clinical approach can adversely affect the 
outcome if adherence is an issue, since adherence 
rates tend to fall with more complex medication 
regimes.5 6 Generally, the decision is based on a 
physician's estimate of adherence, usually gathered 
from interactions within clinical consultations, 
which is known to be inaccurate.7 8 Since very little 
is done in routine clinical care to differentiate phar-
macological and behavioural effects on treatment 
responsiveness, there is a pressing need to differ-
entiate non- responders and poor adherence when 
assessing treatment efficacy. This study explored 
these issues through a new clinical pathway (Cardiff 
Model of Glaucoma Care, CMGC). We undertook 
feasibility, adherence, acceptability and economic 
analyses to determine the utility and feasibility of 
establishing patient non- response rates in the clin-
ical setting.
MATerIAls And MeThods
The study had the following objectives:
1. To recruit glaucoma patients who were shortly 
to commence eye drop treatment and process 
them through the CMGC.
2. To estimate the proportion of participants who 
receive the CMGC as intended.
3. To describe components of the intervention that 
were not received as intended, and reasons why 
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4. To estimate variability in IOP at the various time points.
5. To estimate the proportion of responders to eye drop treat-
ments.
6. To describe variation in participants’ adherence to eye drop 
therapy in the 4 weeks between the initial and follow- up visit.
7. To estimate key resource use.
8. To estimate key cost implications of the CMGC.
study design, setting, sample, sample size
This was a single arm non- randomised prospective observational 
study with primary data collection. Participants were given study 
information sheets prior to obtaining written informed consent 
and all practices followed the guidelines of the Declaration of 
Helsinki.9
Participants were enrolled from four routine glaucoma clinics 
in Wales, UK. Patients were included if: aged 18 years or over; 
diagnosed with either primary open angle glaucoma, ocular 
hypertension, pseudoexfoliative glaucoma, an IOP equal to or 
greater than 21 mm Hg or normal tension glaucoma (NTG) and 
on the point of being prescribed glaucoma eye drops either for 
the first time or after a minimum period of 4 weeks’ discontin-
uation. Patients were excluded if they had any other physical 
conditions that might affect drop efficacy, such as severe arthritis 
or disability.
The study was designed to recruit 60 patient participants 
spread across participating clinics. As this was an observational 
study, a formal a priori power calculation was not possible.10 
However, 60 participants would provide a level of precision 
around a 95% CI. For example, if 80% of participants received 
the CMGC as intended, the 95% CI could be estimated within 
+/-10% (ie, 70% to 90%). The widest the 95% CI would be, if 
the estimated percentage was 50%, was +/-13%.
Primary outcome measures were whether patients and glau-
coma healthcare professionals (HCPs) would accept the CMGC 
format and whether, clinically, a non- response to latanoprost 
could be identified. Acceptability evaluation included data gath-
ered from recruitment, appointment attendance and screening 
logs. We also used qualitative semi- structured interviews 
(patients, n=21, and glaucoma HCPs: doctors, optometrists, 
orthoptists and nurses, n=8), observations of 88 clinical consul-
tations incorporating 50 patients and 10 healthcare professionals, 
as well as a further 52 field notes documenting administrative, 
logistical and organisational aspects to each site’s implementa-
tion. These data provided insight into the acceptability of imple-
menting the CMGC and how the protocol might be amended if 
necessary. All interviews were digitally recorded and transcribed 
verbatim.
Intervention - CMGC
Patients attended two extra clinic visits: (i) within 2 weeks of 
diagnosis to initiate their treatment; and (ii) 4 weeks later. 
Patients were informed of the purpose of the CMGC and given 
their IOP readings at each consultation. At the first visit, baseline 
pressures were measured using calibrated Goldmann applanation 
tonometers before an HCP instilled eye drops and rechecked the 
IOP 4 hours later. While research has indicated that latanoprost 
offers maximal effect 8 to 12 hours post- instillation, Quaranta 
et al have noted significant IOP reductions at 2 hour that would 
indicate an efficacious response.11 12 A 4 hour gap between IOP 
measurements was therefore selected based on balancing the 
practicality of examining patients during core working hours, as 
well as the likelihood of detecting clinical efficacy. At 4 weeks, 
the patient returned to have their IOP measured and another 
eye drop instilled before being asked to come back 4 hours later 
for a further IOP check. Based on their change in IOP over these 
appointments, patients progressed through the CMGC algo-
rithm towards an outcome scenario (figure 1). For example, 
scenario A indicates that patients were responsive to treatment 
within 4 hours of drop instillation and sufficiently adherent after 
4 weeks to maintain a 15% drop in IOP from baseline. Patients 
were then informed of the outcome of the assessments and given 
follow- up appointments for their original clinic. This provided 
opportunity for non- responders to discuss alternative or addi-
tional treatment. The CMGC was conducted by a range of 
trained HCPs: physicians, optometrists, orthoptists and nurses 
and carried out in specialist glaucoma clinics or general ophthal-
mology clinics.
exposures, endpoints and other variables
A case report form collected all research data prospectively; 
this was completed by either nurses, optometrists, doctors or 
the research team. All patients were prescribed latanoprost as 
first- line treatment and, between the two hospital visits, all were 
instructed to instil the eye drop at the same time each evening. 
All patients were given International Glaucoma Association 
booklets on glaucoma/ocular hypertension and advised to speak 
to their clinician if requiring further information.13
We defined non- response to latanoprost as less than a 15% 
reduction of baseline IOP. This level of IOP reduction exceeded 
diurnal variation and would suggest a useful response to 
treatment.14
The following demographic/patient data were collected: age, 
sex, type of glaucoma, primary hand, ethnicity, nationality, post-
code, length of time with eye condition, occupation, smoker 
and an ophthalmic assessment: anterior segment, gonioscopy, 
posterior segment, optic nerve imaging including optical coher-
ence tomography, corrected visual acuity. We also monitored the 
presence of instillation site irritation, nasopharyngitis and other 
ocular adverse events.
To collect study adherence data, participants were asked to 
store their eye drops within a container fitted with an electronic 
monitor in the lid (the Medication Event Monitoring System, 
MEMS),15 retrieving their eye drops from the bottle to take 
them each evening and replacing them afterwards. Patients were 
not informed of the purpose of the bottle. We considered partic-
ipants to have initiated treatment (following their first visit) 
provided that the container was opened at least once. ‘Correct’ 
implementation was defined as instilling eye drops once per day. 
The MEMS bottles were study- specific data collection tools and 
not expected to be integrated more broadly into the CMGC 
pathway.
health economics
To identify the required National Health Service (NHS) resources 
for the CMGC intervention as compared with standard glau-
coma care, qualitative interviews, focus groups and observations 
were carried out in three of the four research sites.
data management and statistical analyses
Statistical analysis
Continuous data were reported as means and SD, or medians and 
IQRs, as appropriate. Categorical data were reported as frequen-
cies and proportions. Outcomes were estimated with associated 
95% CIs. Using the MEMS15 we estimated: (i) the proportion 
of patients initiating their therapy after the first visit,16 and (ii) 
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Figure 1 Revised Cardiff Model of Glaucoma Care (CMGC) intervention algorithm. HCPs, healthcareprofessionals; IOP,intraocular pressure.
using a two- level logistic regression model, accounting for 
repeated observations of days within individuals. The best fitting 
model, as indicated by Akaike’s information criterion, was a 
random intercept and random slope model, with a linear time 
variable fitted as a random effect. For each adherence element, 
we explored variability across clinics, health boards, age, gender 
and baseline IOP by including these as covariates in univariate 
regression analyses. We explored daily adherence separately for 
each of the CMGC responder types.
Health economics analysis
Data were costed and analysed using Unit Costs of Health and 
Social Care.17 A sensitivity analysis was also undertaken to reflect 
variation in staff combinations, ranging from the lowest costing 
qualified staff mix to a more costly, higher grade scenario. NHS 
resources involved in seeking additional clinical advice were also 
included in the analysis.
Qualitative data analysis
Qualitative data were analysed according to framework analysis, 
an explicit and systematic approach to qualitative data analysis.18 19
resulTs
study participants and baseline characteristics
Across the four research sites, 72 participants were screened 
between 12 June 2018 and 21 March 2019, providing 98 
study eyes from 53 eligible participants (figure 2). The study 
was active for each participant over a follow- up period of 4 to 








ol: first published as 10.1136/bjophthalmol-2019-315436 on 4 March 2020. Downloaded from 
4 Waterman H, et al. Br J Ophthalmol 2020;0:1–6. doi:10.1136/bjophthalmol-2019-315436
Clinical science
Figure 2 Consolidated standards of reporting trials diagram 
demonstrating the patient and study eye flow through the Cardiff 
Model of Glaucoma Care appointment structure through to data 
analysis. IOP,intraocular pressure.
Table 1 Baseline characteristics of participants by study eyes
baseline 
characteristics
single eye in 
study
Two eyes in 
study Total
Total no. 8 45 53
Sex, no. (%)       
  Male 5 (62.5) 24 (53.3) 29 (54.7)
  Female 3 (37.5) 21 (46.7) 24 (45.3)
Ethnicity, no. (%)       
  Asian 0 (0.0) 1 (2.2) 1 (1.9)
  Black 0 (0.0) 3 (6.7) 3 (5.6)
  White 8 (100.0) 40 (88.9) 48 (90.6)
  Other 0 (0.0) 1 (2.2) 1 (1.9)
Clinic, no. (%)       
  Clinic 1 5 (62.5) 27 (60.0) 32 (60.4)
  Clinic 2 0 (0.0) 7 (15.6) 7 (13.2)
  Clinic 3 0 (0.0) 6 (13.3) 6 (11.3)
  Clinic 4 3 (37.5) 5 (11.1) 8 (15.1)
Age entering the study 
(years)
      
  Mean (SD) 68 (SD: 6.4) 69 (SD: 10.6) 69 (SD: 10.0)
  Median (range) 68 (57–78) 71 (45–91) 70 (45–91)
Eye condition, no. (%)       
  Normal tension 
glaucoma*
2 (25.0) 9 (20.0) 11 (20.8)
  Ocular hypertension 3 (37.5) 20 (44.4) 23 (43.4)
  Primary open angle 
glaucoma
3 (37.5) 16 (35.6) 19 (35.8)
*Normal tension glaucoma is detection of visual field loss in spite of IOP being 
lower than 21 mm Hg.
IOP, intraocular pressure.
Table 2 Intraocular pressure (IOP) and IOP reduction in study eyes
right eye left eye Total
Baseline IOP (mm Hg)
  No. 48 50 98
  Mean (SD) 22.8 (SD: 4.2) 23.0 (SD: 4.5) 22.9 (SD: 4.1)
  Median (min.–max.) 22.5 (13.7–32.7) 22.7 (11.7–32.3) 22.2 (12.7–30.5)
Mean IOP reduction from 
baseline (%)
Right eye Left eye
  Visit 1.2 21.3 (SD: 14.2) 24.9 (SD: 12.9)
  Visit 2.1 27.1 (SD: 16.2) 26.3 (SD: 14.1)
  Visit 2.2 34.2 (SD: 15.4) 34.2 (SD: 13.7)
Eyes achieving >=15% IOP 
reduction
Right eye Left eye Total
  Visit 1.2 (n; %) 32/47; (68.1) 35/49; (71.4) 67/96; (69.8)
  Visit 2.1 (n; %) 38/46; (82.6) 39/48; (81.3) 77/94; (81.9)
  Visit 2.2 (n; %) 42/45; (93.3) 41/47; (87.2) 83/92; (90.2)
demographic and condition- based characteristics of the patient 
sample by study eye.
After enrolment, three participants (six eyes) were withdrawn 
due to adverse events or failure to attend follow- up appoint-
ments. All other participants completed the study. Five adverse 
events were recorded (1=cardiac issues, 1=blurred vision, 
3=blepharitis) none of which were attributed to eye drop 
instillation.
Clinical IoP reduction
Table 2 outlines the baseline pretreatment mean IOP for treated 
eyes, as well as mean reductions in IOP following each visit. Data 
are available by clinic in online supplementary table 2. The final 
IOP re- measurement (visit 2.2) demonstrated a mean reduction 
from baseline of 34.2% in both right (SD: 15.4; Range: 12.7% 
increase to 65.3% reduction) and left eyes (SD: 13.7; Range: 
3.4% reduction to 58.2% reduction). Table 2 indicates that 83 
of 92 study eyes (90.2%) responded to treatment with an IOP 
reduction exceeding 15% of the baseline IOP.
Most patients (56.1%) fell into CMGC algorithm scenario A. 
The next largest group comprised those responding after 4 weeks 
who were non- responsive after 4 hours (scenario E; 18.4%). 
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accounted for 5.1% of the sample (online supplementary table 
3).
Participant adherence to eye drop therapy
Valid electronic eye drop use data were available for 48/53 
(90.6%) of participants. Invalid data were returned from three 
participants who used the MEMS cap incorrectly (eg, not storing 
their eye drops in the container) and a remaining two were lost 
to follow- up. Valid data were available for 1536 potential dosing 
events over 1376 days. For participants providing valid data, 
all initiated eye drop therapy. Of the 1376 days observed, eye 
drops were instilled as prescribed on 1004 (73% of observed 
days) meaning incorrect instillation on 372 days. Within indi-
viduals the percentage of adherent days ranged from 3.0% to 
100%, and across centres there was minimal variation (online 
supplementary table 4). Where participants did not adhere on a 
given day, the primary indicator for this was that the MEMS cap 
had not been opened (63.2%, or 235/372 days). The MEMS cap 
was opened twice on the same day on 118/372 days (31.7%), 
and three, four and five times on 16, 2 and 1 day, respectively. 
Overall, there was no evidence of a difference in the odds of 
adhering over time (online supplementary table 5).
Variability in 4 hour and 4 week assessments
The target of 4 hour patient returns was largely met for both 
visits 1 and 2 (online supplementary table 6). The time between 
first and second visits was also recorded, the median deviation 
indicating most people returned after 4 and before 5 weeks. 
Those unable to return precisely 4 weeks after their initial visit 
reported conflicts with other clinical appointments, holidays or 
the lack of clinician availability.
Patient and hCP acceptability of CMGC intervention
Data collected from screening logs enabled the initial assessment 
of patient acceptability (figure 2). Of 72 eligible patients, 53 
agreed to take part (73.6%). Refusal was more commonly asso-
ciated with arranging a CMGC appointment within the required 
time frame rather than a perception of the CMGC as overly 
onerous. Additionally, once enrolled into the study most patients 
completed all study procedures (94.3%). During interviews and 
observations, patients considered the clinic to be worthwhile and 
were satisfied with their treatment. Although some patients had 
difficulties with the CMGC intervention because of employment, 
childcare and their distance from the hospital, they still consid-
ered the approach worthwhile (see online supplementary table 7 
for extracts from qualitative patient interviews and observations 
selected to represent a range of interviewees and research sites).
The clinical knowledge and data generated from the CMGC 
were perceived as extremely useful by HCPs. Logistical difficul-
ties in implementation were raised at some sites, predominantly 
around the requirement for 4 hour and 4 week follow- ups, 
which could be difficult to arrange. However, some staff felt that 
the additional effort was worthwhile given the potential of the 
CMGC to improve patient outcomes.
health economics: standard care versus CMGC costings
The additional costs of integrating the CMGC into the health 
service ranged from US$11.20/£9˟ to US$22.40/£18˟, with 
US$16.17/£13˟ as the most plausible marginal cost (see online 
supplementary table 8).17 While the number of patients required 
more staff resources, one clinic felt their model of consecutive 
glaucoma clinics (morning and afternoon) holding one reserved 
place per clinic had no meaningful impact on workload or service 
provision. In services where glaucoma clinics were only held on 
half- days issues with staff availability and potential administra-
tive burdens were reported.
dIsCussIon
Our study demonstrates the feasibility of introducing a new 
pathway in glaucoma clinics to determine whether patients 
respond to glaucoma eye drops. The sample size of 53 partici-
pants and 98 study eyes provided enough data to provide insights 
into the change in IOP and adherence. Although recruitment 
had been expected to be challenging based on patient- perceived 
burden of additional appointments, 73.6% of those approached 
entered the study and 94.3% of those completed all clinical 
procedures, suggesting broad acceptability.
In practice, the CMGC intervention was implemented as 
intended with only occasional deviation in relation to appoint-
ment timings. These were mostly patient- driven and based 
on difficulties in attendance through holidays, other hospital 
appointments or general unavailability. In such cases, patients 
returned at an alternative time to complete their care pathway. 
The level of recruitment between sites varied, with clinics 2, 3 
and 4 each enrolling between six and eight patients, while clinic 
1 offered 32 patients. This was due to issues associated with site 
openings and closures over the study duration but was not felt 
to compromise the sample, instead offering exposure to a wider 
range of sites and research settings than originally intended. The 
estimated additional costs for hosting the CMGC visits were 
marginal, ranging from US$11.20/£9˟ to US$22.40/£18˟ per 
patient across the sampled sites.
Streamlining the CMGC intervention and identifying the core 
aspects that can be readily integrated into existing health board 
structures would help in addressing issues with HCP accept-
ability. Feedback from clinicians suggested the prescribed nature 
of the model negatively affected its implementation potential, a 
key problem being the 4 weekly, rather than the more common 
6 weekly, appointments. We have therefore modified the CMGC 
(figure 1) to maintain its key clinical functionality while reducing 
overly prescriptive aspects to offer smoother implementations. 
Additionally, we have identified that those patients achieving 
sufficient IOP reduction by visit 2.1 (scenarios A and E) need not 
attend visit 2.2 given that treatment efficacy and adherence are 
confirmed. Certainly, for sites where these issues were deemed 
to be less problematic, the benefits of the intervention for clin-
ical data, patient experience and tuition, as well as the potential 
for reduction of future appointments were felt to outweigh the 
logistical problems.
The non- response rate to latanoprost in our sample was 5.1% 
following the removal of adherence as a confounder. This result 
is in line with previous research reporting rates of 4.1%, 13% 
and 21%, respectively, where adherence was controlled and the 
non- response rate cut- off point set at 15%.20–22
Our study demonstrates that the relationship between 
response to treatment and adherence is complex. Previous 
attempts to demonstrate the effect of an adherence intervention 
on IOP have neglected the impact of non- response to eye drops 
on study outcomes.23 Future studies on adherence intervention 
effectiveness will need to take account of non- response to treat-
ment. Reliance on IOP as the primary endpoint for the efficacy 
of adherence intervention studies is also questionable in the 
absence of a robust relationship between adherence as measured 
by the MEMS and IOP. These observations suggest that a change 
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The MEMS has known reliability and validity limitations, 
not least, that it can influence patient adherence since the white 
container can act as a memory aid. Several patients informed us 
they did not use it to store their drops thereby preventing the 
collection of adherence data for these patients. Some patients 
surmised the purpose of the MEMS and perceived it to be a 
‘spy bottle’, possibly affecting its use. Finally, patients could have 
opened the MEMS each day but not instilled their eye drops or 
opened it multiple times each day but not instilled on every occa-
sion. These issues could have affected the accuracy of the adher-
ence data. However, in the absence of a gold standard measure 
it is the best available at present, and perhaps multiple measures 
should be employed to achieve a rounded picture of adherence.
One further discussion point relating to the MEMS is that the 
adherence data were collected once each patient had completed 
visit 2.2 after 4 weeks. This data was often used during patient 
interviews as a means of identifying potential causes for eye 
drops being missed, resulting in reports of social activities, 
holiday transportation and general forgetfulness as barriers to 
adherence. While the MEMS were not intended for the CMGC 
pathway beyond the study, the real- time monitoring of adher-
ence through such technology may be helpful for patient inter-
actions around their own self- medication. There are significant 
ethical issues related to adherence monitoring, though if this 
were posited as a negotiated educational exercise, it could offer 
an avenue to investigate and aid patient engagement with their 
treatment.
In conclusion, it was possible to identify patients not 
responding to latanoprost and thereby reconsider their treatment 
accordingly in routine glaucoma clinics. The non- response rate 
was 5.1% and patients instilled eye drops as per their prescrip-
tion on 73% of observed days. Patients understood the purpose 
of the CMGC and were overwhelmingly prepared to attend. 
HCPs valued the knowledge that was gained from the CMGC 
but the logistical impact and engagement with the CMGC in 
each clinic was contingent on disruption to current workflows. 
The protocol for the CMGC has been amended in the light of 
staff feedback, making it easier to implement.
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